人非小细胞肺癌中蛋白激酶CβⅠ的表达及细胞凋亡与预后关系的研究

Relationship between protein kinase C βⅠ (PKC-βⅠ) expression, apoptosis and prognosis in patients with non-small cell lung cancer

目的 探讨人非小细胞肺癌中蛋白激酶CβⅠ (PKC βⅠ )的表达及细胞凋亡在肺癌发生、发展和预后中的作用。方法 应用免疫组织化学LSAB法和TUNEL法检测 119例人非小细胞肺癌组织、癌旁肺组织和 3 2例肺良性疾病肺组织中PKC βⅠ的表达和凋亡水平。 结果 ( 1)NSCLC组织中PKC βⅠ阳性表达率( 82 .2 7% )显著高于癌旁肺组织 ( 62 .85 % )和肺良性疾病肺组织 ( 5 0 .47% ) (P <0 .0 5 ) ,癌旁肺组织中PKC βⅠ阳性表达率显著高于肺良性疾病肺组织 (P <0 .0 5 )。NSCLC组织中凋亡指数 ( 5 .2 7% )明显低于肺良性疾病肺组织 ( 15 .84% ) (P <0 .0 5 )。 ( 2 )NSCLC组织中PKC βⅠ阳性表达率与肺癌临床病理生理特征无明显关系 (P >0 .0 5 )。NSCLC细胞凋亡水平与肺癌 pTNM分期、原发肿瘤大小及淋巴结转移状态有密切关系 (P <0 .0 5 ) ,而与肺癌细胞分化程度、组织学类型、患者性别和年龄等均无明显关系 (P >0 .0 5 )。 ( 3 )PKC βⅠ阳性表达率与细胞凋亡水平呈显著负相关 (P <0 .0 1)。 ( 4 )PKC βⅠ高表达组肺癌患者术后 5年生存率 ( 7.3 7% )显著低于低表达组患者 ( 3 7.0 6% ) (P <0 .0 1)。肺癌细胞凋亡高水平组患者 5年生存率 ( 3 9.2 4% )显著高于凋亡低水平组患者 ( 6.14 % ) (P <0 .0 1)。

Objective To investigate the relationship between expression of PKC-βⅠ, apoptosis and prognosis of non-small cell lung cancer (NSCLC). Methods The expression of PKC-βⅠ and apoptosis index (AI) were detected in 119 human NSCLC tissues and paracancerous tissues by LSAB and TUNEL, with 32 benign pulmonary disease tissues as control. Results (1)The expression of PKC-βⅠ (82.27%) in NSCLC tissues was significantly higher than those (62.85% and 50.47%) in paracancerous tissues and benign pulmonary disease tissues (P<0.05). The AI (5.27%) in NSCLC tissues was significantly lower than that ( 15.84%) in benign pulmonary disease tissues (P<0.05). (2) No significant relationship was observed between the expression of PKC-βⅠ and clinical physiopathological characteristics of NSCLC (P>0.05). The AI was closely related to pTNM stage of the cancer, size of primary tumor and lymph node metastasis (P< 0.05), but not to the histological classification, cell differentiation, sex and age of the patients with NSCLC (P> 0.05). (3) A highly significant negative correlation was observed between PKC-βⅠ expression and AI in NSCLC group (P<0.01). (4) The 5-year survival rate (7.37%) in patients with high PKC-βⅠ expression was much lower than that (37.06%) in patients with low PKC-βⅠ expression (P<0.01). The 5-year survi-val rate ( 39.24%) in patients with high AI was much higher than that (6.14%) in patients with low AI (P<0.01). Conclusion The abnormal activation of PKC-βⅠ and suppression of apoptosis may play important roles in the oncogenesis and prognosis of lung cancer. Detection of PKC-βⅠ expression and AI may help to predict the prognosis of patients with NSCLC and guide the postoperative multimodality therapy.